SCHEMBL5749

SCHEMBL5749

CC(C)(C)OC(=O)NNCc1ccc(-c2cnccn2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.44
NAMPT P43490 1/20 0.43
CYP2D6 P10635 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
CHRM4 P08173 1/20 0.41
GAA P10253 1/20 0.41
MAOA P21397 1/20 0.40
BRS3 P32247 1/20 0.39
WNT3A P56704 4/20 0.39
RAB9A P51151 1/20 0.39
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP3A4 P08684 1/20 0.38
PORCN Q9H237 1/20 0.38
ATR Q13535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30637051 0.84 TRPV1 (0.44) CYP17A1NAMPTCYP2D6CHRM4GAA
SCHEMBL6692 0.84 TRPV1 (0.44) CYP17A1NAMPTCYP2D6CHRM4GAA
SCHEMBL6234 0.82 NAMPT (0.52) CYP17A1NAMPTWNT3ARAB9ACYP3A4
SCHEMBL17963188 0.79 CYP17A1 (0.53) CYP17A1NAMPTGAARAB9AL3MBTL1
SCHEMBL23081593 0.78 HDAC3 (0.42) CYP17A1NAMPTCYP2C9GAARAB9A
SCHEMBL30525777 0.78 HDAC3 (0.42) CYP17A1NAMPTCYP2C9GAARAB9A
SCHEMBL9439389 0.77 CYP3A4 (0.59) NAMPTCYP2D6CYP2C9GAARAB9A
SCHEMBL6167 0.77 ADRB2 (0.53) CYP17A1GAAL3MBTL1
SCHEMBL6103 0.77 GPR119 (0.42) CYP17A1NAMPTGAARAB9AL3MBTL1
SCHEMBL6447258 0.77 HDAC1 (0.52) CYP17A1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1310905-C Antivirally active heterocyclic azahexane derivatives NOVARTIS AG (CH) 2007-04-18 CN disclosed
CN-1616453-A Antivirally active heterocyclic azahexane derivatives NOVARTIS AG (CH) 2005-05-18 CN disclosed
CN-1193010-C Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 2005-03-16 CN disclosed
EP-0900210-B1 ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES NOVARTIS AG (CH) 2005-02-09 EP disclosed
CN-1082508-C Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 2002-04-10 CN disclosed
CN-1319587-A Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 2001-10-31 CN disclosed
US-6300519-B1 REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND NOVARTIS FINANCE CORPORATION 2001-10-09 US disclosed
US-6166004-A Combinations of HIV protease inhibitors with reverse transcriptase inhibitors NOVARTIS FINANCE CORPORATION (US) 2000-12-26 US disclosed
US-6110946-A AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS NOVARTIS FINANCE CORPORATION (US) 2000-08-29 US disclosed
CN-1216539-A Heterocyclic azahexane derivatives with antiviral activity NOVARTIS AG (CH) 1999-05-12 CN disclosed
EP-0900210-A1 ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES Novartis AG (CH) 1999-03-10 EP disclosed
US-5849911-A Antivirally active heterocyclic azahexane derivatives NOVARTIS FINANCE CORPORATION (US) 1998-12-15 US disclosed
WO-1997040029-A1 ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES NOVARTIS AG (CH) 1997-10-30 WO disclosed